Hemogenyx Pharmaceuticals to issue convertible loan notes

2025-09-02 16:03

Hemogenyx Pharmaceuticals (OTCPK:HOPHF) issued convertible loan notes as the company continues the clinical trial of HG-CT-1, its CAR-T cell therapy for relapsed or refractory acute myeloid leukemia.
The company was approached by a small investor group offering to provide funding to support the ongoing clinical trial.
To support the clinical trial, the company has raised £620,000 through the issuance of CLNs at a fixed conversion price of £5.30 per share, being the closing share price on 29 August 2025.
The CLNs, which are non-interest bearing, will automatically convert following an increase in the company's headroom restrictions under the FCA's Prospectus Rules, allowing for the issuance of conversion shares without requiring an approved prospectus.
This conversion is expected to take place on or after 15 November 2025.

More on Hemogenyx Pharmaceuticals